45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
4,159
Insurances with rates
16
CPT / HCPCS codes
2,343
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J9347 | IMJUDO 300MG/15ML | $261,261 | $156,757 | — | — | 19 |
| J9334 | VYVGART-HYT 1008-11200MG VL | $106,989 | $64,193 | — | — | 19 |
| 33249 | INS/RPL DEFIB W/LEAD | $93,552 | $56,131 | — | — | 19 |
| J2350 | OCREVUS 300MG/10ML INJECTION | $90,295 | $54,177 | — | — | 19 |
| J9272 | JEMPERLI 500MG/10ML VIAL | $66,651 | $39,991 | — | — | 19 |
| J2327 | SKYRIZI 600MG/10ML | $61,647 | $36,988 | — | — | 19 |
| C1882 | ICD GALLANT HFCRT-D | $54,390 | $32,634 | — | — | 12 |
| J9119 | LIBTAYO 350MG/7ML VIAL | $53,074 | $31,844 | — | — | 19 |
| J9316 | PHESGO 600MG-600 MG | $51,835 | $31,101 | — | — | 19 |
| J9022 | ATEZOLIZUMAB 1200MG/20ML INJ | $49,346 | $29,608 | — | — | 19 |
| J9144 | DARZALEX FASPRO | $44,174 | $26,504 | — | — | 19 |
| J9228 | YERVOY 5MG/ML INJ 10ML | $39,863 | $23,918 | — | — | 19 |
| C1721 | ICD GALLANT DR | $39,690 | $23,814 | — | — | 12 |
| J9223 | ZEPZELCA 4 MG VIAL | $38,687 | $23,212 | — | — | 19 |
| J9332 | VYVGART 400MG/20ML | $38,245 | $22,947 | — | — | 19 |
| 0795T | TCAT INS 2CHMBR LDLS PM CMPL | $38,142 | $22,885 | — | — | 19 |
| 0796T | TCAT INS 2CHMBR LDLS PM RA | $38,142 | $22,885 | — | — | 19 |
| 0797T | TCAT INS 2CHMBR LDLS PM RV | $38,142 | $22,885 | — | — | 19 |
| 0801T | TCAT RMV&RPL 2CHMBR LDLS PM | $38,142 | $22,885 | — | — | 19 |
| 0802T | TCAT RMV&RPL2CHMB LDLS PM RA | $38,142 | $22,885 | — | — | 19 |
| 0803T | TCAT RMV&RPL2CHMB LDLS PM RV | $38,142 | $22,885 | — | — | 19 |
| J9311 | RITUXAN HYC 1400MG/11.7ML | $36,545 | $21,927 | — | — | 19 |
| J9301 | GAZYVA 1000MG/40ML VIAL | $35,864 | $21,518 | — | — | 19 |
| J3101 | TNKASE 50MG INJ | $35,210 | $21,126 | — | — | 19 |
| J3380 | VEDOLIZUMAB 300MG/5ML VIAL | $33,883 | $20,330 | — | — | 19 |
| J7169 | ANDEXXA 200MG VIAL | $33,655 | $20,193 | — | — | 19 |
| J2506 | NEULASTA 6MG 0.6ML INJECTION | $33,007 | $19,804 | — | — | 19 |
| J9308 | RAMUCIRUMAB 500MG/50ML INJ | $30,832 | $18,499 | — | — | 19 |
| A2025 | MIRO3D 100 CM3/CM3 | $30,557 | $18,334 | — | — | 12 |
| J2406 | KIMYRSA 1200MG VIAL | $29,886 | $17,932 | — | — | 19 |
| 37236 | TRNSCTH STENT INIT ART | $29,607 | $17,764 | — | — | 26 |
| 37238 | TRNSCTH STENT INIT VEIN | $29,607 | $17,764 | — | — | 19 |
| C9600 | PRC DES+PLST 1 VSL LC | $29,488 | $17,693 | — | — | 19 |
| C9601 | PERC DES+PLSTY ADD LD | $29,488 | $17,693 | — | — | 12 |
| C9602 | PERC DES+ATH+PLSTY LD | $29,488 | $17,693 | — | — | 19 |
| C9604 | REV BP GRF W/DES LC | $29,488 | $17,693 | — | — | 19 |
| C9606 | REV MI W/DES 1 VSL LC | $29,488 | $17,693 | — | — | 12 |
| C9607 | REV CH W/DES 1 VSL RC | $29,488 | $17,693 | — | — | 19 |
| 34708 | ENDOVASC RPR ILIO-ILIAC RPT | $29,342 | $17,605 | — | — | 12 |
| 33229 | RMV+REPL PM GEN MULT | $28,862 | $17,317 | — | — | 19 |
| J9356 | HERCEPTIN HYLECTA 600MG SDV | $28,609 | $17,165 | — | — | 19 |
| CATH LIGHTENING FLASH 100CM | CATH LIGHTENING FLASH 100CM | $28,606 | $17,164 | — | — | 12 |
| 37242 | VASC OCCLUSION ARTERIAL | $28,439 | $17,063 | — | — | 19 |
| J9177 | PADCEV 30 MG VIAL | $28,227 | $16,936 | — | — | 19 |
| 37244 | VASC OCCLUSION AV HEMRG | $28,197 | $16,918 | — | — | 19 |
| J9306 | PERJETA 420MG/14ML INJECTION | $27,854 | $16,712 | — | — | 19 |
| 36903 | SHUNT STDY W/ANGIO+STNT | $27,434 | $16,460 | — | — | 19 |
| J9271 | KEYTRUDA VIAL 100MG/4ML | $26,225 | $15,735 | — | — | 19 |
| J1569 | GAMMAGARD 10% 30GM | $25,447 | $15,268 | — | — | 19 |
| 93459 | LT HEART CATH LV+BP GRF | $25,228 | $15,137 | — | — | 26 |
Showing top 50 of 4,159 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.